P&G to support on-site care for London 2012 Olympic Games athletes
CINCINNATI — Procter & Gamble’s Crest + Oral-B have teamed up to help dentists ensure the best oral health for the athletes of the London 2012 Olympic Games.
As part of the partnership, Crest + Oral-B will support LOCOG in its provision of the London 2012 dental clinic. This facility will provide dental screenings, routine dental work, emergency care and oral care products for athletes and coaches for the duration of the 2012 Games.
In addition, Crest + Oral-B have partnered with Dr. Tony Clough, a dental expert who works with the British rowing team, the Alpine ski team and the British boxing team, providing advice, protective equipment and dental care to help improve the understanding of oral care and how it relates to an athlete’s performance.
Clough led the dental clinic during the Beijing 2008 Olympic Gamesand calls the implementation of the on-site resource an important milestone. In fact, in an International Olympic Committee evaluation of the health of athletes following the Beijing Olympic Games, it was determined that dental care is of utmost importance to promote good athletic function and the ability of the athlete to compete at an optimal level without being compromised by dental disease or an otherwise preventable emergency.
Clough and Crest + Oral-B are working to ensure that this message continues outside of the London 2012 Olympic Games as well, and are providing the athletes and their coaches with the Oral-B Pro-Expert suite of products, including Oral-B Pro-Expert Toothpaste, Oral-B CrossAction Pro-Expert toothbrushes, Oral-B floss and fluoridated mouthwash.
An estimated 2,000 to 3,000 Olympic athletes, coaches and officials are expected to visit the dental clinic during the 2012 Olympic Games.
StriVectin names new CEO, elevates Melisse Shaban to chairman
NEW YORK — Anti-aging skin care brand StriVectin announced that Melisse Shaban has been elevated to chairman and JuE Wong has been appointed CEO.
"StriVectin’s growth surge continues on the back of our clinically proven, unique technology," Shaban stated. "We are on a tear — and we needed to enhance our leadership team to support this growth. We intend to continue to delight and surprise our consumers and provide unrivalled support to our retail partners. We are thrilled to have JuE’s unique skills to take us to the next level."
Wong joins StriVectin following a long career in the beauty industry. Most recently, she served as CEO of Astral Health & Beauty. Prior to Astral, Wong held senior leadership positions at ZO Skin Health by Dr. Obagi, N.V. Perricone M.D. Cosmeceuticals, and Murad.
"JuE’s international experience and direct channel experience will be invaluable in our next phase of growth," Shaban stated. "The reformulation of the StriVectin line with the breakthrough proprietary NIA 114 technology is now complete. Women around the world are enjoying the benefits of younger looking skin through cellular level molecular regeneration — we are truly making the world younger looking and more beautiful, one face at a time. We are incredibly fortunate to have JuE’s proven leadership skills to help us grow this revolution, in an industry that has traditionally offered more hope than results. In my continuing role as chairman, I will focus more heavily on strategy and technological innovation."
"I am pleased to join the talented team at StriVectin and share their confidence in StriVectin’s continued growth and product innovation opportunities," Wong added. "StriVectin’s reputation as a leader in scientific innovation is evident in its proprietary NIA-114 technology, rooted in over 30 years of research into DNA repair and skin cancer prevention. In recognition of this dedication to technology, StriVectin has been awarded numerous industry accolades, including the ‘Skin Sense Award’ by the Skin Cancer Foundation and ‘2012 Winner — Prestige Moisturizer’ by Cosmetic Executive Women. In joining StriVectin, I see an opportunity to build on these successes by continuing to launch technologically innovative products and further strengthen our retail partnerships across the globe."
Lilly announces negative results in schizophrenia drug trial
INDIANAPOLIS — A clinical trial of a drug for schizophrenia did not yield the desired results, the drug’s developer said.
Eli Lilly announced results of the H8Y-MC-HBBM study of pomaglumetad methionil, for patients with acute exacerbation of schizophrenia. The company said results did not show the drug produced a significantly different effect from the placebo.
"Unfortunately, negative studies are common in the field of psychiatry and a reality of biopharmaceutical innovation," Lilly Research Labs EVP science and technology and president Jan Lundberg said. "Despite all of the advances, the need for new and better treatments for those suffering with mental illnesses is among the most urgent in medicine."